Lantern Pharma Inc.
LTRNNASDAQHealthcareBiotechnology
Previous close
$2.34
+$0.05 · +2.18%
LTRN company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
26
Expensive
Momentum
56
Neutral
Sentiment
66
Bullish
Risk resilience
23
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteLantern Pharma Inc. is a clinical-stage biotechnology firm dedicated to revolutionizing drug development through the strategic application of artificial intelligence, machine learning, and comprehensive genomic data analysis. Their primary drug candidate, LP-100, is currently undergoing Phase II clinical trials, targeting metastatic, castration-resistant prostate cancer. The company is also advancing LP-300 as a potential combination therapy for non-small cell lung cancer adenocarcinoma, specifically in individuals who are non-smokers or have never smoked. Furthermore, their preclinical pipeline includes LP-184, an alkylating agent engineered to inflict DNA damage upon cancer cells that either overexpress specific biomarkers or exhibit mutations within their DNA repair pathways. Beyond these, Lantern Pharma maintains an antibody-drug conjugate (ADC) program for diverse cancer treatments. Central to their operations is the RADR artificial intelligence platform, which synergizes molecular data through advanced big data analytics and machine learning capabilities. Established in 2013, the company operates from its headquarters in Dallas, Texas.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Panna Sharma
- Listed since
- Jun 11, 2020
- Employees
- 16
Market position
Day range
Current $2.34
52-week range
Current $2.34
- Open
- $2.335
- Previous close
- $2.29
- Volume
- 185.08K
- 0.86× average
- Average volume
- 214.65K
- Average daily volume
- Market cap
- 29.86M USD
- Beta
- 2.34
- Market reference 1
- 50-day average
- $3.1742
- -26.28% below average
- 200-day average
- $2.9948
- -21.86% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 107.14M USD
- EV / EBITDA
- -6.26×
- Earnings yield
- -51.84%
- Free cash flow yield
- -47.48%
Profitability & efficiency
- Return on equity
- -262.00%
- Return on assets
- -155.13%
- Return on invested capital
- -21.13%
Financial health
- Current ratio
- 2.4×
Financial statements
Income trends
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | — | — | 174.84K USD | — | — |
| Gross profit | — | — | −174.84K USD | — | — |
| Research and development | 11.51M USD | 16.13M USD | 11.89M USD | 8.6B USD | 7.57M USD |
| Selling, general, and administrative | 6.46M USD | 6.09M USD | 5.98M USD | 5.83B USD | 5.02M USD |
| Operating expenses | 17.98M USD | 22.22M USD | 17.7M USD | 14.43B USD | 12.59M USD |
| Interest income | 437.93K USD | 742.36K USD | 765.39K USD | 204.36M USD | 67.93K USD |
| Depreciation and amortization | 17.28K USD | 17.28K USD | 174.84K USD | — | 6.76K USD |
| Operating income | −17.98M USD | −22.22M USD | −17.88M USD | −14.43B USD | −12.59M USD |
| Net income | −17.12M USD | −20.78M USD | −15.96M USD | −14.26B USD | −12.36M USD |
Company facts updated Aug 24, 2026.
Earnings
- EPS beat rate
- 73%
- 8 beats, 3 misses, 0 met estimates
- Average EPS surprise
- +5.62%
- 11 comparable reports
- Latest EPS result
- -0.57
- Estimate -0.38 · Miss by 50.00%
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Rating distribution
3 ratingsLimited analyst sample: 3 ratings. Interpret the distribution with caution.
LTRN news
LTRN peers
ETFs holding LTRN
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI889.95K0.00%2.3T USD0.03%$378.24+0.44%
Vanguard Extended Market ETFVXF215.4K0.00%93.7B USD0.05%$245.53+0.82%
Horizon Kinetics Medical ETFMEDX53.23K0.30%17.8M USD0.85%$37.545+1.67%
Dimensional - US Sustainability Core 1 ETFDFSU4.41K0.00%2.35B USD0.15%$48.20+0.52%
Dimensional - US Core Equity 2 ETFDFAC1.47K0.00%49.31B USD0.17%$45.61+0.46%Vanguard Morningstar Total Stock Market ETFVTI- Market value
- 889.95K
- Weight
- 0.00%
- AUM
- 2.3T USD
- Expense ratio
- 0.03%
- Price / 1D
- $378.24+0.44%
Vanguard Extended Market ETFVXF- Market value
- 215.4K
- Weight
- 0.00%
- AUM
- 93.7B USD
- Expense ratio
- 0.05%
- Price / 1D
- $245.53+0.82%
Horizon Kinetics Medical ETFMEDX- Market value
- 53.23K
- Weight
- 0.30%
- AUM
- 17.8M USD
- Expense ratio
- 0.85%
- Price / 1D
- $37.545+1.67%
Dimensional - US Sustainability Core 1 ETFDFSU- Market value
- 4.41K
- Weight
- 0.00%
- AUM
- 2.35B USD
- Expense ratio
- 0.15%
- Price / 1D
- $48.20+0.52%
Dimensional - US Core Equity 2 ETFDFAC- Market value
- 1.47K
- Weight
- 0.00%
- AUM
- 49.31B USD
- Expense ratio
- 0.17%
- Price / 1D
- $45.61+0.46%
Continue in GoAI
Research LTRNresearch.disclaimer